**Core tip: The** Hispanic population represents a major contributor to the hepatocellular carcinoma (HCC) burden. However, our current study demonstrates that over 60% of Hispanic HCC patients were ineligible for liver transplantation given the extent of disease severity. This advanced cancer stage at diagnosis likely reflects suboptimal implementation of early and timely HCC screening and surveillance in high-risk populations. These findings emphasize the need to be more vigilant about HCC screening and surveillance, especially among the Hispanic population.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide\[[@B1]-[@B3]\]. The number of deaths per year from HCC is nearly identical to the worldwide incidence, highlighting the incredibly high case fatality rate of this aggressive disease\[[@B3]\]. While the highest prevalence of HCC is among populations in Asia and Africa, the incidence of HCC has been increasing in the United States, due to the growing number of patients with nonalcoholic steatohepatitis (NASH) and chronic hepatitis C virus (HCV) who are at risk for HCC\[[@B1],[@B4]-[@B8]\]. However, the rising HCC incidence is not uniform across all groups, and an increasingly disproportionate rise in HCC incidence among minority groups, and in particular Hispanics, have been reported\[[@B9]-[@B13]\]. A recent study by White et al\[[@B7]\] reported a 4.5% annual increase in overall HCC incidence in the United States from 2000 to 2009. However, race/ethnicity-specific differences were observed with significantly greater increases in HCC incidence among Hispanics, such that beginning in 2012, HCC incidence among Hispanics surpassed that of Asians in the United States. While the exact etiology underlying this epidemiology is unclear, these trends likely reflect the successful impact of HBV vaccination in Asians and the emergence of nonalcoholic fatty liver disease (NAFLD) in the Hispanic population. Because the Hispanic population carries a disproportionate burden of NAFLD, understanding trends in HCC among the Hispanic population in the United States may provide insight on NAFLD-HCC trends\[[@B11],[@B14]-[@B19]\]. The aim of the current study is to evaluate overall trends and disparities in HCC outcomes among Hispanic HCC patients in the United States with a focus on HCC tumor stage at presentation.

MATERIALS AND METHODS
=====================

The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) population based cancer registry was reviewed to identify all Hispanic adults (age 20 years and older) with HCC from 2004 to 2014 in the United States\[[@B20]\]. The 2004-2014 SEER data includes data from 18 regions in the United States (San Francisco-Oakland, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Natives, Rural Georgia, California excluding San Francisco/San Jose/Los Angeles, Kentucky, Louisiana, New Jersey, and Greater Georgia) and represents approximately 28% of the United States population.

The International Classification of Disease for Oncology, Third Edition was used by the SEER database to define HCC\[[@B21]\]. HCC tumor stage was evaluated using SEER historic summary staging, which is unique to SEER and is not used particularly for prognosis, but to describe the extent of disease\[[@B21]\]. Tumors confined to only one lobe of the liver with or without vascular invasion were defined as localized. Tumors involving more than one lobe through contiguous growth of a single lesion, extension to adjacent structures (gallbladder, diaphragm, or extrahepatic bile ducts), or spread to regional lymph nodes were defined as regional. Metastatic disease or extension of cancer to distant lymph nodes or nearby organs such as the stomach, pleura, or pancreas was defined as distant. In addition to SEER HCC staging, we also evaluated tumor characteristics including size and number of tumors to determine whether a patient's tumor met Milan criteria (single lesion less than 5 cm or no more than 3 lesions each less than 3 cm) with no extrahepatic or vascular involvement. We specifically chose to evaluate whether or not a patient's tumor met Milan criteria, as this affects eligibility for liver transplantation, which is one of the major curative treatment options for HCC\[[@B22]\].

Insurance status was evaluated using SEER classifications, which included three categories: Medicare or commercial insurance, Medicaid, and uninsured/no insurance. Medicare or commercial insurance includes patients with private insurance (fee-for-service, managed care, HMO, PPO, Tricare) or Medicare (administered through a managed care plan, Medicare with private supplement, or Medicare with supplement, NOS and Military). Medicaid includes patients with Medicaid (including administered through managed care plans, Medicare with Medicaid eligibility, and Indian/Public Health Service). Uninsured is defined as those who were either not insured or self-pay at time of HCC diagnosis. Age-specific comparisons utilized three categories of age at time of HCC diagnosis (age \< 50 years, age 50 - 64 years, and age \> 65 years).

Statistical analysis
--------------------

Demographic characteristics of the study cohort were presented as proportions and frequencies. Overall proportion of adult Hispanic patients with localized HCC or HCC within Milan criteria were stratified by sex, age at time of diagnosis, insurance status, and year of diagnosis, and compared across groups using *χ^2^* test. Predictors of HCC tumor stage at presentation and HCC treatment received were evaluated using multivariate logistic regression models. Forward stepwise regression methods were used with variables demonstrating significant associations in the univariate model (*P \<* 0.10) or those with biologic significance determined a priori (*e.g*., age and sex) included in the final model. Statistical significance was met with a 2-tailed *P*-value \< 0.05. All statistical analyses were performed with Stata version 14 (Stata Corp, College Station, TX). The study was reviewed and determined to be exempt by the Alameda Health System Institutional Review Board because human subjects were not involved, as per United States Department of Health and Human Services guidelines, and the SEER database is publicly available without individually identifiable private information.

RESULTS
=======

Hispanics accounted for 19.8% of all HCC among United States adults in the 2004-2014 SEER registry, with the majority of subjects with HCC being men (*n =* 9856, 73.3%). Among both Hispanic men and women with HCC, 60.9% had Medicare or commercial insurance at time of HCC diagnosis, 33.5% had Medicaid, and 5.6% were uninsured (Table [1](#T1){ref-type="table"}). The proportion of the HCC cohort represented by Hispanic patients increased from 17.6% in 2004-2006 to 20.1% in 2013-2014.

###### 

Characteristics of the study cohort

                              **Hispanics**   **Asians**   **Non-Hispanic White**                 
  --------------------------- --------------- ------------ ------------------------ ------ ------ -------
  Sex                                                                                             
  Female                      26.7            3584         29.5                     3273   24.9   9273
  Male                        73.3            9856         70.6                     7840   75.1   27940
  Age                                                                                             
  \< 50 yr                    10.7            1440         10.7                     1191   6.1    2268
  50-64 yr                    47.1            6325         36.4                     4045   45.6   16973
  \> 65 yr                    42.2            5675         52.9                     5877   48.3   17972
  Insurance                                                                                       
  Medicare or Commercial      60.9            5969         66.3                     5177   80.2   21265
  Medicaid                    33.5            3280         29.5                     2299   16.1   4257
  Uninsured                   5.6             549          4.3                      335    3.7    983
  Year of diagnosis                                                                               
  2004-2006                   17.6            2722         17.6                     2713   51.8   8009
  2007-2008                   17.4            2115         16.3                     1985   52.5   6376
  2009-2010                   18.9            2550         15.4                     2084   51.3   6927
  2011-2012                   20.1            2870         13.9                     2133   51.9   7690
  2013-2014                   20.1            3183         13.9                     2198   51.7   8211
  HCC SEER summary stage                                                                          
  Localized                   54              6091         51.8                     2250   52.6   8644
  Regional                    29.5            3324         31                       1345   31.2   5129
  Distant                     16.5            1858         15                       747    16.2   2652
  HCC within Milan criteria                                                                       
  No                          62              8337         59.1                     2832   55.4   10530
  Yes                         38              5103         40.9                     1958   44.6   8465

HCC: Hepatocellular carcinoma; SEER: Surveillance, Epidemiology, and End Results.

When evaluating HCC tumor stage at diagnosis, 38.0% of Hispanic HCC patients were within Milan criteria, and 54.0% of Hispanic HCC patients had localized HCC (Table [2](#T2){ref-type="table"}). Compared to female HCC patients, male HCC patients had significantly lower rates of localized HCC (52.8% *vs* 57.6%, *P \<* 0.001) and significantly lower rates of HCC within Milan criteria (37.4% *vs* 39.7%, *P* = 0.01). Compared to HCC patients age \< 50 years at time of diagnosis, higher rates of localized HCC and HCC within Milan criteria were observed in those age 50-64, but HCC patients age \> 65 years had lower rates of localized HCC or HCC within Milan criteria (Table [2](#T2){ref-type="table"}). Compared to Medicare or commercially insured patients, Hispanic HCC patients with Medicaid or no insurance had significantly lower rates of localized HCC or HCC within Milan criteria.

###### 

Proportion of Hispanic hepatocellular carcinoma patients with localized hepatocellular carcinoma or hepatocellular carcinoma within Milan criteria at time of diagnosis

                           **Localized HCC at Time of diagnosis**   **HCC within Milan criteria at time of diagnosis**                            
  ------------------------ ---------------------------------------- ---------------------------------------------------- ---------- ------ ------ ----------
  Total                    54                                       6091                                                            38     5103   
  Sex                                                                                                                                             
  Female                   57.6                                     1680                                                 \< 0.001   39.7   1422   0.01
  Male                     52.8                                     4411                                                            37.4   3681   
  Age                                                                                                                                             
  \< 50 yr                 51.7                                     630                                                  \< 0.01    36.8   530    \< 0.001
  50-64 yr                 55.5                                     3030                                                            44.6   2820   
  \> 65 yr                 52.9                                     2431                                                            30.9   2753   
  Insurance                                                                                                                                       
  Medicare or Commercial   56.2                                     3004                                                 \< 0.001   42.7   2547   \< 0.001
  Medicaid                 53.8                                     1607                                                            42.9   1407   
  Uninsured                39.4                                     191                                                             29.9   164    
  Year of Diagnosis                                                                                                                               
  2004-2006                52.8                                     1195                                                 \< 0.001   33.4   908    \< 0.001
  2007-2008                31.7                                     553                                                             33.8   714    
  2009-2010                52.7                                     1368                                                            37.3   951    
  2011-2012                56.3                                     1368                                                            40.9   1173   
  2013-2014                56.9                                     1525                                                            42.6   1357   

HCC: Hepatocellular carcinoma.

When stratified by year of HCC diagnosis, Hispanic HCC patients in the latter time periods had significantly higher rates of localized HCC at time of diagnosis, and in 2013-2014, 56.9% of Hispanic HCC patients had localized tumor stage. Similarly, the proportion of Hispanic patients with HCC within Milan criteria also increased with time, and in 2013-2014, 42.6% of Hispanic HCC patients were within Milan criteria (Table [3](#T3){ref-type="table"}). When stratified by sex, age, and insurance status, similar trends were seen, such that HCC patients in latter time periods had the highest rates of more localized stage of disease.

###### 

Trends in the proportion of Hispanic hepatocellular carcinoma patients with localized hepatocellular carcinoma and hepatocellular carcinoma within Milan criteria over time

  **Localized HCC**      **Overall**   **Female**   **Male**   **Age \< 50**   **Age 50-64**   **Age 65 and over**   **Uninsured**   **Medicaid**   **Medicare/Commercial**                                                                              
  ---------------------- ------------- ------------ ---------- --------------- --------------- --------------------- --------------- -------------- ------------------------- ---------- ------- ---------- ------- --------- ------- ---------- ------- ----------
  2004-2006              52.8          1195         58         342             51              853                   48.7            165            54.1                      544        52.9    486        \-      \-        \-      \-         \-      \-
  2007-2008              31.7          553          55.5       236             48.1            635                   46              115            50.9                      424        50.1    332        33.9    38        49.3    281        52.1    531
  2009-2010              52.7          1368         55.3       588             51.8            844                   51.5            121            55.4                      589        49.6    422        36      40        52.6    397        54.4    675
  2011-2012              56.3          1368         58         363             55.7            1005                  60.2            121            57.5                      706        54.1    541        39.6    53        56.4    456        58      835
  2013-2014              56.9          1525         59.7       451             55.7            1074                  56              108            57.6                      767        56.1    650        46.9    60        55.5    473        58.4    963
  *P*-Value                            \< 0.001                \< 0.03                         \< 0.001                              \< 0.02                                  \< 0.02            \< 0.01            0.17              0.14               \< 0.001
  **HCC Within Milan**   **Overall**   **Female**   **Male**   **Age \< 50**   **Age 50-64**   **Age 65 and Over**   **Uninsured**   **Medicaid**   **Medicare/Commercial**                                                                              
                         **%**         ***n***      **%**      ***n***         **%**           ***n***               **%**           ***n***        **%**                     ***n***    **%**   ***n***    **%**   ***n***   **%**   ***n***    **%**   ***n***
  2004-2006              33.4          908          34.6       255             34.3            653                   32.9            141            39.9                      462        26.4    305        \-      \-        \-      \-         \-      \-
  2007-2008              33.8          714          32.8       179             35.5            535                   34.1            105            40.6                      397        25.2    212        27.5    36        37.8    237        37.6    428
  2009-2010              37.3          951          40.6       260             35.3            691                   36.2            97             45.5                      559        28.2    295        30.3    37        40.1    337        40.4    558
  2011-2012              40.9          1173         41.1       310             40.2            863                   40.8            92             47.7                      676        33.1    405        30.7    47        47.5    420        42.4    687
  2013-2014              42.6          1357         46.1       418             36.8            939                   41.2            95             47.1                      726        30.9    536        30.8    44        44.2    413        47.8    874
  *P*-Value                            \< 0.001                \< 0.001                        \< 0.001                              0.3                                      \< 0.001           \< 0.001           0.92              \< 0.001           \< 0.001

HCC: Hepatocellular carcinoma.

On multivariate regression, in comparison to Medicare/commercially insured Hispanic HCC patients, uninsured patients were significantly less likely to have HCC within Milan criteria at time of diagnosis (OR 0.49, 95%CI: 0.40-0.59, *P \<* 0.001), whereas no significant difference was observed in Medicaid HCC patients (Figure [1](#F1){ref-type="fig"}). Compared to 2004-2006, Hispanic HCC patients in both the 2011-2012 and 2013-2014 cohorts were significantly more likely to have HCC within Milan criteria at diagnosis (2011-2012: OR 1.17, 95%CI: 1.04-1.32, *P* = 0.007; 2013-2014: OR 1.30, 95%CI: 1.16-1.45, *P \<* 0.001). Compared to patients age \< 50 years at the time of diagnosis, Hispanic HCC patients age 65 years and older were significantly less likely to have HCC within Milan criteria (OR 0.67, 95%CI: 0.58-0.79, *P \<* 0.001), whereas patients age 50-64 years old were significantly more likely to have HCC within Milan criteria (OR 1.33, 95%CI: 1.15-1.54, *P \<* 0.001). Males were less likely than females to be within Milan criteria (OR 0.76, 95%CI: 0.68-0.83, *P \<* 0.001) (Figure [1](#F1){ref-type="fig"}).

![Multivariate logistic regression model evaluating predictors of hepatocellular carcinoma within Milan criteria at diagnosis. These data specifically evaluate the independent risk of having hepatocellular carcinoma (HCC) within Milan criteria at diagnosis when evaluated by insurance status at time of diagnosis, the year of HCC diagnosis, the age at time of HCC diagnosis, sex, and marital status. An odds ratio of \> 1.00 indicates increased likelihood of having HCC within Milan criteria at time of diagnosis.](WJH-10-956-g001){#F1}

Similar trends were observed when evaluating predictors of SEER localized stage of HCC at diagnosis. Uninsured Hispanic HCC patients and those with Medicaid were significantly less likely to have localized disease compared to those patients with Medicare or commercial insurance (Uninsured: OR 0.43, 95%CI: 0.33-0.55, *P* \< 0.001, Medicaid: OR 0.85, 95%CI: 0.74-0.97, *P* = 0.018). Patients diagnosed with HCC during 2013-2014 were more likely to have localized disease as compared to those diagnosed from 2004-2006 (OR: 1.28, 95%CI: 1.08-1.52, *P* = 0.004), however there was no significant difference when comparing 2011-2012 or 2007-2008 to 2004-2006. Males were less significantly less likely to have localized disease compared to females (OR 0.79, 95%CI: 0.68-0.91, *P* = 0.001) (Figure [2](#F2){ref-type="fig"}).

![Multivariate logistic regression model evaluating predictors of localized stage hepatocellular carcinoma at diagnosis. These data specifically evaluate the independent risk of having localized cancer stage hepatocellular carcinoma (HCC) at diagnosis compared to advanced cancer stage when evaluated by insurance status at time of diagnosis, the year of HCC diagnosis, the age at time of HCC diagnosis, sex, and marital status. An odds ratio of \> 1.00 indicates increased likelihood of having localized cancer stage HCC at time of diagnosis.](WJH-10-956-g002){#F2}

DISCUSSION
==========

Using United States population-based cancer registry data, the current study evaluated disparities in HCC tumor stage at diagnosis with a focus on Hispanics with HCC. Overall, the proportion of HCC in the Hispanic population increased during the study period such that over 20% of HCC patients in the United States during 2013-2014 were of Hispanic ethnicity. Despite this huge disease burden among the Hispanic population, less than half of Hispanic HCC patients were within Milan criteria at the time of diagnosis in the most recent time period studied. Furthermore, significant disparities among this group were observed, with a disproportionately higher risk of advanced tumor stage at presentation among Hispanic men, older Hispanic patients, and uninsured Hispanic patients.

Nearly one in five HCC patients in the United States are of Hispanic ethnicity with Hispanic patients showing the greatest increase in the incidence of HCC from 2004-2006 to 2013-2014\[[@B20]\]. These observations are consistent with previous SEER registry based studies evaluating trends in HCC incidence. For example, El-Serag et al\[[@B23]\] reported significantly greater age-adjusted HCC incidence rates in Hispanic patients in comparison to non-Hispanic white and black populations between 1992 and 2002. This increasing HCC incidence among the Hispanic population in the United States has continued to rise such that HCC incidence among Hispanics surpassed HCC incidence among Asians in 2012 to become the ethnic group with the greatest incidence of HCC in the United States and representing over 20% of all HCC among adults in the United States\[[@B7]\]. While our current study is limited by the ability to evaluate the liver disease etiology contributing to HCC, the Hispanic population in the United States carries a disproportionate burden of NAFLD\[[@B14]-[@B17],[@B24]-[@B28]\]. Furthermore, during this same period where Hispanics have become the ethnic group with the most rapidly rising incidence of HCC, it is also important to note that prevalence of NASH-related HCC has also risen in parallel\[[@B8],[@B18],[@B26],[@B29]-[@B31]\]. Two recent studies using the SEER-Medicare database and the United Network for Organ Sharing registry demonstrate the continued rising prevalence of NAFLD-related HCC in the United States\[[@B8],[@B18]\].

While the growing burden of HCC among the Hispanic population is concerning, it is even more alarming that the Hispanic population faces significant disparities in access to treatment options for HCC, which contributes to significantly lower survival\[[@B32]-[@B35]\]. A recent study by Ha et al\[[@B34]\] using the SEER database found that Hispanic patients with HCC had significantly lower rates of curative HCC treatment when compared to non-Hispanic whites. Hispanics were also significantly less likely to receive liver transplantation even after correcting for stage of disease at time of diagnosis. Our current analysis of the most recent SEER database continues to highlight these disparities among the Hispanic HCC population. Despite improvements in earlier tumor stage of diagnosis over time, even in the most recent 2013-2014 period only 42.6% of Hispanic HCC patients were within Milan criteria at the time of diagnosis, which means that nearly 60% of patients were not eligible for liver transplantation, one of the main curative options for HCC patients.

A greater frequency of HCC was observed among male patients within our study, which is consistent with prior data showing HCC rates in males are two to four times as high as rates in females\[[@B35],[@B36]\]. This sex-specific trend in HCC risk is also observed among NAFLD HCC populations. Corey et al\[[@B36]\] evaluated at risk factors for HCC in 94 patients with NAFLD with HCC and 150 patients with NAFLD without HCC. The strongest association with risk of HCC was being male, with males having a four-fold higher risk of developing HCC compared to females. The majority of Hispanic HCC patients in our study were men, and they had more advanced HCC at diagnosis compared to females. Similarly Yang et al\[[@B37]\] observed significantly better outcomes in females with HCC. In their study of primarily non-Hispanic Caucasian patients, the distribution of tumor burden showed a higher incidence of single lesions among women and a higher incidence of vascular invasion among men.

Our study utilized a large population-based cancer registry, which represents a large proportion of the United States population. The SEER registry allowed for a large sample size and comprehensive analysis of HCC epidemiology and outcomes. Despite this, the current study has several limitations that should be acknowledged. SEER does not include etiology of HCC (*e.g*., chronic hepatitis B virus, chronic HCV, alcoholic liver disease, or NAFLD), which may have affected rates of disease progression or rates of timely HCC screening and surveillance. Along the same lines, liver disease-specific treatment data (*e.g*., antiviral therapies) were not available for inclusion in the analysis. While our study observed more advanced tumor stage among older patients, this observation may be confounded by other factors. Older patients may have had more significant co-morbidities (hypertension, diabetes mellitus, or cardiac disease) that may have affected referral for HCC screening and surveillance. However, these additional co-morbidities and risk factors such as alcohol use, obesity, and concurrent diabetes mellitus were not available in the database for inclusion in our analyses. While our study also investigated disparities related to insurance status, we acknowledge that insurance status is only one key factor that is tightly linked to other demographic and socioeconomic factors in a complex manner. Furthermore, in the SEER database, Medicare and commercially insured patients are combined into one category, and demographic and clinical differences between those with Medicare and commercial insurance may affect HCC stage at diagnosis. However, access to care, including HCC screening and surveillance that would affect tumor stage and HCC treatment are expected to be similar between those with Medicare and commercial insurance in the United States. While our study found significant disparities in HCC stage among uninsured patients, these differences may reflect difficulty accessing healthcare due to complex socioeconomic needs. However, these data were not available to assess further in the database. Another factor not readily available for analysis is concurrent substance use and high-risk behavior, which may have affected timely access and adherence to HCC surveillance. Lastly, surveillance data were not available to evaluate how the differences in successful screening and surveillance rates contributed to the observed disparities in HCC stage at diagnosis. Despite these limitations, our study provides valuable information regarding a vulnerable subset of the United States population.

Understanding HCC trends provides valuable data to guide clinicians and policy makers to identify high-risk groups as well as those that suffer disparities towards which resources can be targeted to improve HCC screening and surveillance for early detection and treatment. Our current study focused specifically on Hispanic HCC patients, a group that has the highest incidence of HCC in the United States since 2012 and represents 20% of all adults with HCC. Among this group less than 40% had HCC within Milan criteria at the time of diagnosis, and thus over 60% were ineligible for liver transplantation, one of the major curative options for HCC patients. Part of this problem revolves around effective HCC screening and surveillance, and despite established guidelines, overall HCC screening rates remain low\[[@B38]-[@B40]\]. In one United States population-based study, less than 20% of patients with cirrhosis who developed HCC received regular surveillance, and only 29% of patients who had a diagnosis of HCC had undergone annual surveillance in the three years before receiving the diagnosis\[[@B41]\]. Tavakoli et al\[[@B42]\] observed that less than half of cirrhotic patients received first time HCC screening among safety-net populations with cirrhosis, with the largest disparity occurring among patients with NASH cirrhosis. Improved efforts at HCC screening and surveillance are needed, particularly among Hispanic patients, a growing population with a high prevalence of NAFLD.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Hepatocellular carcinoma (HCC) is a leading cause of morbidity and mortality worldwide. The Hispanic population represents a major contributor of HCC prevalence, particularly in the United States. Understanding HCC epidemiology and disparities in HCC outcomes among this cohort will help guide interventions to improve HCC care.

Research motivation
-------------------

Given the significant burden of HCC among the Hispanic population, understanding HCC epidemiology and outcomes among this group is critical. Data gathered from studying HCC epidemiology can help identify potential areas where quality improvement programs can be developed and implemented to improve management of HCC.

Research objectives
-------------------

The main objective of this study was to evaluate disparities in cancer stage at diagnosis among Hispanic HCC patients.

Research methods
----------------

The current study utilized a large United States national-based cancer registry. We utilized a retrospective observational cohort study design to evaluate HCC epidemiology and outcomes among Hispanic adults diagnosed with HCC from 2004 to 2014.

Research results
----------------

We identified that over 60% of Hispanic HCC patients were diagnosed with advanced cancer stage that was beyond eligibility for liver transplantation. This highlights an important disparity and may reflect suboptimal utilization of timely HCC screening and surveillance among this population.

Research conclusions
--------------------

These findings may suggest that the Hispanic population at risk for HCC may experience suboptimal receipt of or delays in timely HCC screening and surveillance. These study findings further add to the existing literature highlighting the poor adherence to HCC screening and surveillance among at-risk populations. Specifically, our study identified a high-risk group in the Hispanic population, which is particularly concerning given the higher risk of nonalcoholic fatty liver disease in this population, a disease that is increasing in prevalence.

Research perspectives
---------------------

Our study findings emphasize the importance of timely and consistent implementation of HCC screening and surveillance that will translate into improved early HCC detection. This will ultimately improve treatment options for curative intent and thus improve long-term survival outcomes among HCC patients.
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